New Insights on Treating Neurodegeneretive Diseases Could Lead to New Classes of Clinical Trials for Alzheimer’s Disease

 

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly mice, found that a unique gene in their genetically-mutated mice activated dormant neural stem cells, in effect generating new neurons in the brain. This discovery to awaken stem cells may lead to new clinical trials for treating people with neurodegenerative diseases, including an estimated 6.5 million Americans ages 65 and older who are living with Alzheimer’s in 2022.

With the increasing number of people developing these diseases, will there be many more discoveries down the road? Overall, clinical trials for Alzheimer’s disease medications are giving new options to patients.

“Alzheimer’s research is getting to a place where cancer research was maybe 30, 40 years ago,” says Anton Porsteinsson, MD, director of the Alzheimer’s Disease Care, Research and Education Program at the University of Rochester Medical Center in New York, as quoted in the Association of American Medical Colleges News. “I think we’re at a point where we’re going to see a logarithmic increase in discovery.”

Dr. Dung Trinh, MD, Chief Medical Officer of the Healthy Brain Clinic, which provides individualized plans for brain health with coaching and support including memory testing and brain health exams, gives his perspective on this new research and helps track the implications of this research for neurobiologists and for patients with neurodegenerative diseases.

Dung’s Thoughts

“Neural degeneration, otherwise known as the loss of brain cells, is a very common thread among pretty much all the neural degenerative diseases we have in the brain that includes Alzheimer’s disease and other dementias such as vascular dementia. It includes multiple sclerosis and Parkinson’s disease. The one underlying thread is the loss of brain cells, otherwise known as neurodegeneration.

So, this research actually is very exciting. We have not found a strategy to reproduce successfully more brain cells that have been less with these neurodegenerative diseases. And the best we’ve had so far is to hopefully try to slow down neurodegeneration, but the ability to create more brain cells, especially from stem cells that have been inactive in the brain, is a very exciting new revelation.

And this will lead to new classes of clinical trials and studies that will revolutionize this field. The field of neurodegeneration unfortunately have not caught up as far as finding new treatments and finding new medications due to the fact that we have not been able to successfully create or find a way to make new brain cells consistently. ”

Article written by Sonya Young.

Follow us on social media for the latest updates in B2B!

Image

Latest

Texas
Policy, Patients, and the Future of Healthcare: How Texas Plans to Fix a Strained System
May 4, 2026

The U.S. healthcare system is under real strain—and it’s something both patients and physicians are feeling in everyday care. In Texas, those pressures are even more visible, where rapid population growth, rural access challenges, and regulatory complexity are making it harder for patients to get timely care and for doctors to focus on medicine…

Read More
adaptive learning
Scaling Career-Ready Skills: How Adaptive Learning and Generative AI Are Transforming Higher Education
May 4, 2026

Skills-based learning has moved from buzzword to mandate as colleges face mounting pressure to connect credentials, employability, and measurable learner outcomes. Employers are increasingly using skills-based hiring practices, and NACE’s Job Outlook 2026 notes that students need to demonstrate concrete examples of skills in action during hiring processes. At the same time, higher education…

Read More
Gen Alpha
A Gen Alpha Take on Experiential Retail: What Works, What Doesn’t, and What’s Missing
May 4, 2026

Gen Alpha is no longer a future consumer segment—they are already shaping how retail and entertainment experiences are designed today. Research from MG2 shows that a whopping 70% of Gen Alpha influence what adults in their lives purchase, reshaping brand decisions faster than many companies are prepared for. As experiential retail continues to evolve—with…

Read More
TGR Foundation
Tiger Woods’ TGR Foundation Is Reimagining Education Through Learning Labs and Hands-On STEM Experiences
May 4, 2026

Education systems around the world are under pressure to evolve faster than ever, especially for underserved communities. In the U.S. alone, millions of students in low-income households still lack access to STEM resources and career pathways—fueling a widening opportunity gap. For more than 30 years, the TGR Foundation, founded by Tiger Woods, has worked…

Read More